NANOTOXO : vaccine to treat ovine toxoplasmose
Description
Design of a subunit vaccine administered by mucosal or intradermal route and using polysaccharidic nanoparticles with lipidic heart.
The nanoparticles are able to deliver the antigens to the immune cells and induce a strong cellular response protective against toxoplasmosis infection.
Benefits:
- Injection by mucosal route,natural route of infection, or intradermal route
- Raises a protective cellular response without stimulating a strong humoral response
- Protects against abortion and cyst formation
- Long shelf life, stable
- Able to support cold chain rupture, multidose vaccine
Sheet
Download the offer